Evidence map›Paper›PMID 38489198›Full record

ReviewJournal of Parkinson's disease2024

Perspectives of People At-Risk on Parkinson's Prevention Research.

Jessi L Keavney, Soania Mathur, Karlin Schroeder, Ray Merrell, Sergio A Castillo-Torres, Virginia Gao, Grace F Crotty, Michael A Schwarzschild, John M Poma

Open access · diamondAbstract readReview
In one paragraph

Review in Journal of Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Designing the First Trials for Parkinson's Prevention.Journal of Parkinson's disease · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Jessi L KeavneyParkinson's Foundation, Parkinson's Advocates in Research Program, Pendergrass, GA, USA.
Soania MathurUnshakeable MD, Toronto, ON, Canada.
Karlin SchroederParkinson's Foundation, Associate Vice President of Community Engagement, New York, NY, USA.
Ray MerrellRBD Advocate, NJ, USA.
Sergio A Castillo-TorresEdmond J. Safra Fellow in Movement Disorders, Servicio de Movimientos Anormales, Fleni, Buenos Aires, Argentina.
Virginia GaoMovement Disorders Fellow, Columbia University Irving Medical Center and Weill Cornell Medicine, New York, NY, USA.
Grace F CrottyDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Michael A SchwarzschildDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
John M PomaParkinson's Foundation, People with Parkinson's Advisory Council, Glen Allen, VA, USA.
Harvard University · USParkinson's Foundation · USCornell University · USParkinson Research Foundation · US

Funding

Planning for Prevention of Parkinson's disease: A Trial Design ForumR13NS129235 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CROTTY, GRACE · 2022 to 2022
$25k
NINDS NIH HHS R13 NS129235
6 · The paper itself

Abstract

The movement toward prevention trials in people at-risk for Parkinson's disease (PD) is rapidly becoming a reality. The authors of this article include a genetically at-risk advocate with the LRRK2 G2019 S variant and two patients with rapid eye movement sleep behavior disorder (RBD), one of whom has now been diagnosed with PD. These authors participated as speakers, panelists, and moderators in the "Planning for Prevention of Parkinson's: A Trial Design Forum" hosted by Massachusetts General Hospital in 2021 and 2022. Other authors include a young onset person with Parkinson's (PwP) and retired family physician, an expert in patient engagement in Parkinson's, and early career and veteran movement disorders clinician researchers. Several themes emerged from the at-risk participant voice concerning the importance of early intervention, the legitimacy of their input in decision-making, and the desire for transparent communication and feedback throughout the entire research study process. Challenges and opportunities in the current environment include lack of awareness among primary care physicians and general neurologists about PD risk, legal and psychological implications of risk disclosure, limited return of individual research study results, and undefined engagement and integration of individuals at-risk into the broader Parkinson's community. Incorporating the perspectives of individuals at-risk as well as those living with PD at this early stage of prevention trial development is crucial to success.

Indexed as

Parkinson DiseaseBiomedical ResearchGenetic Predisposition to DiseaseHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MaleREM Sleep Behavior DisorderLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanGBAhyposmiaLRRK2Parkinson’s diseasepatient advocacypatient engagementpreventionREM sleep behavior disorderrisk

Identifiers

PMID38489198
PMCPMC11091608
OpenAlexW4392845496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.